Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside G(M3): Involvement of receptor-directed protein tyrosine phosphatase(s)

被引:38
作者
Pestana, ES
Greiser, U
Sanchez, B
Fernandez, LE
Lage, A
Perez, R
Bohmer, FD
机构
[1] CTR INMUNOL MOL, HAVANA 11600, CUBA
[2] UNIV JENA, FAC MED, MAX PLANCK SOC, RES UNIT MOL CELL BIOL, D-07747 JENA, GERMANY
关键词
epidermal growth factor receptor; monoclonal antibody; ganglioside G(M3); growth inhibition; protein tyrosine phosphatases;
D O I
10.1038/bjc.1997.36
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Growth of the EGF receptor-expressing non-small-cell lung carcinoma cell line H125 seems to be at least partially driven by autocrine activation of the resident EGF receptors. Thus, the possibility of an EGF receptor-directed antiproliferative treatment was investigated in vitro using a monoclonal antibody (alpha EGFR ior egf/r3) against the human EGF receptor and gangliosides which are known to possess antiproliferative and anti-tyrosine kinase activity. The moderate growth-inhibitory effect of alpha EGFR ior egf/r3 was strongly potentiated by the addition of monosialoganglioside G(M3). Likewise, the combination of alpha EGFR ior egf/r3 and G(M3) inhibited EGF receptor autophosphorylation activity in H125 cells more strongly than either agent alone. A synergistic inhibition of EGF receptor autophosphorylation by alpha EGFR ior egf/r3 and G(M3) was also observed in the human epidermoid carcinoma cell line A431. In both cell lines, the inhibition of EGF receptor autophosphorylation by G(M3) was prevented by pretreatment of the cells with pervanadate, a potent inhibitor of protein tyrosine phosphatases (PTPases). Also, G(M3) accelerated EGF receptor dephosphorylation in isolated A431 cell membranes. These findings indicate that G(M3) has the capacity to activate EGF receptor-directed PTPase activity and suggest a novel possible mechanism for the regulation of cellular PTPases.
引用
收藏
页码:213 / 220
页数:8
相关论文
共 59 条
[2]   RECEPTOR BLOCKADE WITH MONOCLONAL-ANTIBODIES AS ANTICANCER THERAPY [J].
BASELGA, J ;
MENDELSOHN, J .
PHARMACOLOGY & THERAPEUTICS, 1994, 64 (01) :127-154
[3]   THE EPIDERMAL GROWTH-FACTOR RECEPTOR AS A TARGET FOR THERAPY IN BREAST-CARCINOMA [J].
BASELGA, J ;
MENDELSOHN, J .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 29 (01) :127-138
[4]  
BERGH J, 1981, ANTICANCER RES, V1, P317
[5]  
BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133
[6]  
BERGH J, 1982, ACTA PATH MICRO IM A, V90, P149
[7]   THE DEPHOSPHORYLATION CHARACTERISTICS OF THE RECEPTORS FOR EPIDERMAL GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR IN SWISS 3T3-CELL MEMBRANES SUGGEST DIFFERENTIAL REGULATION OF RECEPTOR SIGNALING BY ENDOGENOUS PROTEIN-TYROSINE PHOSPHATASES [J].
BOHMER, FD ;
BOHMER, SA ;
HELDIN, CH .
FEBS LETTERS, 1993, 331 (03) :276-280
[8]   USE OF SELECTIVE TYROSINE KINASE BLOCKERS TO MONITOR GROWTH-FACTOR RECEPTOR DEPHOSPHORYLATION IN INTACT-CELLS [J].
BOHMER, FD ;
BOHMER, A ;
OBERMEIER, A ;
ULLRICH, A .
ANALYTICAL BIOCHEMISTRY, 1995, 228 (02) :267-273
[9]  
BREMER EG, 1986, J BIOL CHEM, V261, P2434
[10]  
CARNEY DN, 1985, CANCER RES, V45, P2913